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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMBackground: The frequency and prognostic impact of bleeding after hospital
discharge for PCI has not been well studied. We sought to identify the incidence,
predictors and prognostic impact of post-discharge bleeding (PDB) after percutaneous
coronary intervention (PCI) at 2 years.
Methods: ADAPT-DES was a prospective, multicenter registry of patients success-
fully treated with one or more drug-eluting stents. Patients were stratiﬁed and 2-year
outcomes according to the occurrence of PDB.
Results: Among 8,582 patients who underwent PCI in ADAPT-DES, PDB occurred in
610/8,577 hospital survivors (7.1%) at median time of 210 [17, 453] days after the index
procedure. Gastrointestinal bleeding (n¼208; 34.1%) was the most frequent type of PDB.
Independent predictors of PDB were in-hospital bleeding (HR [95%CI] ¼ 12.27
[9.92,15.16], P< 0.0001), warfarin use at discharge (HR [95%CI] ¼ 1.60 [1.23, 2.09],
P¼0.0005), presence of coronary calciﬁcation (HR [95%CI] ¼ 1.27 [1.06, 1.51],
P¼0.008), lower creatinine clearance (HR [95%CI] ¼ 1.04 [1.02, 1.07], P¼0.002), pe-
ripheral arterial disease (HR [95%CI]¼ 1.40 [1.13, 1.75], P¼0.003), andVerifyNowPRU
208 (HR [95%CI] ¼ 1.20 [1.01, 1.43], P¼0.03). PDB was strongly associated with 2-
year adverse outcomes (Table). By multivariable analysis, including the occurrence of
myocardial infarctionpost-discharge as a time-dependent co-variable, PDBwas a powerful
independent predictor of 2-year mortality (HR [95%CI]¼ 3.91 [2.90, 5.27], P< 0.0001).
Conclusions: PDB after DES occurs within 2 years in w1 in 14 patients, and is
strongly predictive of long-term mortality.Table 2. Two-year Outcomes According to Post-discharge Bleeding
Post-discharge Bleeding
(n¼610)
No Post-discharge Bleeding
(n¼7967) P-value
Death 70 (11.8) 241 (3.2) <0.0001
Cardiovascular 39 (6.8) 154 (2.1) <0.0001
Non-cardiovascular 31 (5.3) 87 (1.2) <0.0001
Myocardial infarction 60 (10.7) 209 (2.8) <0.0001
Q-wave 8 (1.4) 38 (0.5) 0.006
Non Q-wave 52 (9.3) 176 (2.4) <0.0001
Deﬁnite /probable ST 8 (1.4) 76 (1.0) 0.38
Major adverse cardiac
events
124 (21.5) 645 (8.5) <0.0001
Target vessel failure 195 (32.6) 968 (12.8) <0.0001
Data presented as n (%); major adverse cardiac events is a composite of cardiac death,
myocardial infarction or target lesion revascularization; Target vessel failure is a composite of
death, myocardial infarction and target vessel revascularization; ST¼stent thrombosis
Table 1. Freedom from 1-year MACE: ORBIT II Males vs Females
Males Females p-value
Freedom from MACE (%) 83.5 83.8 0.88
Freedom from cardiac death (%) 96.1 98.7 0.15
Freedom from MI (%) 89.9 91.1 0.67
Freedom from Q-wave MI (%) 99.0 99.3 0.67
Freedom from Non-Q-wave MI (%) 90.9 91.7 0.77
Freedom from TVR/TLR (%) 94.6 93.3 0.61
MACE: major adverse cardiac events; MI: myocardial infarction; TVR: target vessel revascu-
larization; TLR: target lesion revascularization
p-values from Cox Proportional Hazards ModelAtherectomy and Plaque Modiﬁcation
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Diamondback 360 Coronary Orbital Atherectomy System for Treating De Novo,
Severely Calciﬁed Coronary Lesions in Elderly Patients: 1-Year Results from the
ORBIT II Trial
Arthur Lee1, Jeffrey Chambers2
1Cardiac & Vascular Institute, Gainesville, United States, 2MHVI Minneapolis, MN,
Minneapolis, United States
Background: Percutaneous coronary intervention (PCI) in elderly patients is associated
with higher rates of complications and worse short term prognosis. This may be due to
increased co-morbidities including renal disease, tortuous vascular anatomy, and
calciﬁed arteries. For these reasons, elderly patients are excluded from many clinical
trials, leading to a paucity of evidence to determine optimal therapy for these patients. In
this analysis, we evaluate the 1-year outcomes of elderly patients in the ORBIT II Trial.
Methods: ORBIT II (443 patients, 49 US sites) is the ﬁrst prospective trial to
exclusively study patients with severely calciﬁed coronary lesions. The Diamondback
360 Coronary Orbital Atherectomy System (OAS) (Cardiovascular Systems, Inc.,
St. Paul, MN) was used to modify and prepare lesions prior to stent placement. The
major adverse cardiac event (MACE) rate was examined at one-year in patients
75 years of age (N¼174) and < 75 years of age (N¼269).
Results: Patients 75 years of age were more likely to be former smokers, have lower
eGFR at baseline, lower body mass index at baseline, as well as higher prevalence of
history of hypertension and stroke. The total length of calcium in patients 75 years
of age was longer compared to patients < 75 years of age (30.6  1.3 mm vs. 27.1 
1.0 mm, p¼0.01). As estimated by Kaplan Meier at 1-year, patients 75 years of ageJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Atand patients < 75 years of age had similar high freedom from MACE (82.7% vs.
84.2%, p¼0.67), myocardial infarction (MI) (89.1% vs. 91.1%, p¼0.50), non-Q-wave
MI (89.7% vs. 92.2%, p¼0.37), Q-wave MI (99.4% vs. 98.9%, p¼0.56), target vessel
revascularization/target lesion revascularization (TVR/TLR) (94.1% vs. 94.2%,
p¼0.97) and cardiac death (97.1% vs. 96.9%, p¼0.93).
Conclusions: Despite more complex lesions elderly patients with severely calciﬁed
coronary arteries had similar outcomes compared to younger patients when treated
with the Diamondback 360 Coronary OAS to facilitate stent delivery.
TCT-129
Gender Differences in 1-Year Outcomes in Patients Treated with the
Diamondback 360 Coronary Orbital Atherectomy System: Results from the
ORBIT II Trial
Christopher Kim1, Jeffrey Chambers2
1Utah Cardiology, PC, Layton, UT, 2MHVI Minneapolis, MN, Minneapolis,
United States
Background: A negative correlation between female gender and some in-hospital
adverse events after percutaneous coronary intervention (PCI) has been reported. In
this analysis, we evaluate the 1-year outcomes of male and female patients in the
ORBIT II Trial.
Methods: The prospective ORBIT II Trial enrolled 443 patients at 49 sites in the U.S.
and patients were treated with the Diamondback 360 Coronary Orbital Atherectomy
System (OAS) (Cardiovascular Systems, Inc., St. Paul, MN) to prepare de novo,
severely calciﬁed coronary lesions for stent placement. In this analysis, the 1-year
major adverse cardiac event (MACE) rate, deﬁned as myocardial infarction (MI),
cardiac death, and target vessel revascularization (TVR) was evaluated in male
(N¼286) and female (N¼157) ORBIT II patients as estimated by Kaplan-Meier.
Results: At baseline compared to males, females were older (73.3  0.8 vs 70.4 
0.6, p¼0.001) and had lower mean eGFR (71.3  2.1 vs 78.2  1.5, p¼0.002). Males
had a higher rate of previous coronary artery bypass graft (18.2% vs 8.3%, p¼0.005).
The rate of successful stent delivery (96.8% vs 99.4%, p¼0.11) and < 50% residual
stenosis (98.2% vs 99.4%, p¼0.43) was similar in males and females, respectively. As
shown in Table 1, both males and females had high freedom from 1-year MACE.Conclusions: Preparation of severely calciﬁed coronary lesions with the Diamond-
back 360 Coronary OAS to facilitate stent deployment results in high rates of freedom
from 1-year MACE, irrespective of gender.
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Andrew J. Markwick3, James C. Spratt4, Mark Gunning3, John Greenwood1
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Background: Rotational atherectomy (RA) is an effective way to mechanically
debulk heavily calciﬁed lesions before stenting. We sought to identify procedural
factors associated with long term cardiovascular outcome.
Methods: Retrospective evaluation of all patients who underwent RA and PCI in three
large UK tertiary cardiac centres (Leeds General Inﬁrmary, Royal Inﬁrmary of
Edinburgh and University Hospital of North Staffordshire) from 14/3/2005 to
18/1/2013. MACE was deﬁned as cardiac death, MI and TVR.
Results: 518 patients (mean age 71.5+/-9.3yrs) had RA with mean follow-up 27.6+/-
17.3 months. 68.3% were male, 28.7% had diabetes mellitus (DM) and 34.6% were
treated because of ACS. 974 stents were implanted in 97.3% of the cases
(75.9% DES). 30.7% performed transradially and 32.7% used a GP IIb/IIIa inhibitor.
Maximum burr size was 1.75mm in 85.5% of patients; mean SYNTAX score
19.5+/-11.6. Procedural complications occurred in 6.3% patients and vascular com-
plications in 2.1%. Outcomes in the follow up period were: MACE 18.7%, all-cause
death 13.7%, cardiac death 6.6%, MI 11.2%, TVR 7.5%, deﬁnite stent thrombosis
(ST) 1.2% and stroke 2.9%. Patients with intermediate and high syntax scores (>22
and >32) were more likely to have an MI, ST, MACE, cardiac death or death from
any cause (table 1). Patients with a syntax score >32 were more likely to have aherectomy and Plaque Modiﬁcation B39
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comprocedural complication. Multiple logistic regression analysis showed that the pres-
ence of peripheral vascular disease (PVD) (p¼0.024, OR¼1.9), DM (p¼0.002,
OR¼2.2), ACS presentation (p¼0.013, OR¼1.9) and SYNTAX score (p< 0.001,
OR¼1.047) had a signiﬁcant impact on MACE.
Conclusions: RA is a complex but safe procedure typically performed in elderly high-
risk patients with calciﬁed lesions. Higher syntax scores >22 and>32 were associated
with higher rates of death, MI, TVR and ST. PVD, DM, ACS presentation and syntax
score are signiﬁcant predictors for MACE.Table 1. Outcomes by SYNTAX category.
SYNTAX22 SYNTAX>22 p-value SYNTAX32 SYNTAX>32 p-value
Total 334 181 443 72
Cardiac Death 12 (3.6%) 21 (11.6%) 0.001 21 (4.7%) 12 (16.7%) 0.001
Death 33 (9.9%) 37 (20.4%) 0.002 47 (10.6%) 23 (31.9%) <0.001
TVR 22 (6.6%) 17 (9.4%) 0.295 33 (7.4%) 6 (8.3%) 0.81
MI 25 (7.5%) 33 (18.2%) <0.001 41 (9.3%) 17 (23.6%) 0.001
Stent Thrombosis 0 (0%) 6 (3.3%) 0.002 4 (0.9%) 2 (2.8%) 0.199
Stroke 8 (2.5%) 7 (4.2%) 0.284 11 (2.6%) 4 (5.9%) 0.139
MACE 45 (13.5%) 51 (28.2%) <0.001 70 (15.8%) 26 (36.1%) <0.001
Vascular complications 7 (2.1%) 4 (2.2%) 1 10 (2.3%) 1 (1.4%) 1
Procedural
complications
16 (4.8%) 16 (8.8%) 0.085 22 (5.0%) 10 (13.9%) 0.008TCT-131
Tissue Removal Assessment with Ultrasound of the SFA and Popliteal Study
(TRUTH): Orbital Atherectomy Acute Data and Intravascular Ultrasound
Analysis
Anvar BABAEV1, Susanna Zavlunova2, Michael Attubato3, Akiko Maehara4
1NYU MEDICAL CENTER, NEW YORK, NY, 2NYU Langone Medical Center,
New York, NY, 3New York University School of Medicine, New York, NY,
4Cardiovascular Reserach Foundation and Columbia University Medical Center,
New York, United States
Background: Percutaneous removal of atherosclerotic material using atherectomy
devices may offer an alternative approach for improving procedural success. The
TRUTH study (24 patients) evaluated the removal of plaque with the Orbital Athe-
rectomy System (OAS) (Cardiovascular Systems, Inc., St. Paul, MN) by analyzing
changes in plaque volume/composition via an independent virtual histology (VH)-
intravascular ultrasound (IVUS) Core Laboratory at CRF.
Methods: Lesions in the superﬁcial femoral artery, popliteal, and/or tibioperoneal
trunk were treated with the OAS followed by adjunctive balloon angioplasty (BA).
IVUS images were collected during 1) pre-treatment; 2) post-OAS; and 3) post-BA.
Results: The mean age was 70.4 years and 36% of patients had a history of renal
insufﬁciency, diabetes (72%), hyperlipidemia (100%), hypertension (100%), and
smoking (84%). The mean lesion and calcium length assessed via angiography was
65.4+27.8mm and 55.431.6 mm, respectively. The baseline Rutherford Classiﬁcation
(RC) of 3 (96.0%) changed RC of 0 (100% asymptomatic) at 2 week follow-up. No
incidence of recoil, slow ﬂow/no reﬂow, ﬂow-limiting dissections or perforations were
reported. VH-IVUS analysis revealed that the minimum lumen area increased from 4.0
mm2 to 9.1 mm2 post-procedure (< 0.0001) accompanied with decrease of area stenosis
(Table). At the maximum calcium ablation site, the lumen area also increased and cal-
cium reduction was responsible for 86% [35%, 100%] of the lumen increase. The arc of
reverberation increased from 22 to 39 (p¼0.05) and the prevalence of convex shape of
calcium surface decreased indicating device-related modiﬁcation of calcium.Pre Post-OAS Post-BA
p-value
(overall)
p-value (pre vs
post-OAS)
Lesion analysis (n¼24 lesions)
Minimum lumen area, mm2 4.0 [2.2,
4.9]
4.7 [3.2,
5.9]
9.1 [7.8,
10.5]
<0.0001 0.072
Area stenosis, % 77 [61, 81] 64 [58, 77] 43 [27, 56] <0.0001 0.067
Mean vessel area, mm3/mm 31.4 [26.1,
35.2]
31.8 [25.9,
37.8]
34.5 [31.9,
40.3]
<0.0001 0.21
Mean lumen area, mm3/mm 8.5 [5.0,
9.9]
8.9 [8.1,
11.1]
12.9 [11.7,
15.2]
<0.0001 0.037
Mean plaque area, mm3/mm 22.1 [18.5,
28.1]
22.1 [18.1,
26.2]
21.9 [17.9,
25.3]
0.04 0.7
Calciﬁed plaque analysis (28 calciﬁed plaques)
Lumen area, mm2 6.2 [4.7,
8.7]
8.4 [6.4,
10.9]
12.2 [11.2,
14.9]
<0.0001 0.0013
Area stenosis, % 58 [29, 69] 38 [11, 45] 16 [10, 42] <0.0001 <0.0001
Convex shape of surface of
calcium, %
54 39 29 0.011 0.21
Reverberation, % 25 39 36 0.095 0.11
Arc of reverberation,  22 [18, 24] 39 [27, 60] 28 [20, 47] 0.43 0.05
% of Calcium Reduction out of
Lumen Gain
– 86 [35,100] – – –
OAS¼orbital atherectomy system; BA¼balloon angioplasty
B40 JACC Vol 64/11Conclusions: The orbital atherectomy system (OAS) is effective at reducing and
modifying calcium from lesions, resulting in low acute complications and improved
Rutherford Classiﬁcation.
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Long-term Costs of Directional Atherectomy vs. Other Treatment Choices for
Diabetes Patients with Peripheral Artery Disease: a 24-Month Analysis of
Administrative Claims Data
Khusrow Niazi1, Katrine L. Wallace2, Michael Grabner3
1Emory University, Alpharetta, GA, 2Covidien, Mansﬁeld, MA, 3HealthCore, Inc.,
Wilmington, DE
Background: Directional atherectomy is an endovascular therapy that is effective in
the treatment of diabetic and non-diabetic patients with peripheral artery disease
(PAD). This study was undertaken to assess the all-cause healthcare costs of direc-
tional atherectomy as well as other therapies used in treating diabetic patients with
PAD over 24-months post-treatment.
Methods: PAD patients were selected from a large claims database with 1 CPT code
for a lower extremity PAD procedure between 2005-2011. The date of the ﬁrst CPT
code was the index date. Patients were included with: 12-months of pre-index date
continuous medical and pharmacy eligibility; 1 PAD ICD-9-CM code within
6 months prior to the index date; 1 medical claim for Type 2 Diabetes Mellitus
during baseline; and 18 years of age on index date. Multivariate models to evaluate
risk of hospitalization during follow-up and all-cause health care cost at 24 months
were constructed, controlling for covariates.
Results: 8,121 patients had both diabetes and PAD, with a mean age of
67.6 years and 39% were female. Endovascular treatments received for PAD treat-
ments were: stent (26%), peripheral bypass (23%), PTA+stent (22%), PTA (16%),
PTA+atherectomy (4%), atherectomy (4%), unspeciﬁed (4%), and PTA+stent+
atherectomy (1%). At 24-months post-procedure (N¼3,721), the atherectomy group
had the lowest mean healthcare costs ($49,588) while bypass had the highest
($62,340). After controlling for covariates, there were no statistically signiﬁcant dif-
ferences between atherectomy and any of the other treatments with respect to all-cause
health care costs over 24 months. Atherectomy patients were also not statistically
signiﬁcantly more likely than any of the other therapies to be hospitalized during
follow-up.
Conclusions: Diabetics tend to have a higher re-stenosis rate and are thought to have
more complex disease versus non-diabetic patients. Among PAD patients with dia-
betes in this large claims database, directional atherectomy was associated with similar
re-hospitalization rates and similar or lower costs compared to other PAD therapies
over 24 months.Thrombectomy
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Residual Intrastent Thrombus After Primary Angioplasty Is Associated With
MACE At Follow Up. Insight From The COCTAIL II Study
Laura Gatto1, fabrizio imola1, Enrico Romagnoli2, Tomasz Pawlowski3,
Silvio Fedele4, Valeria Marco2, Giulia Paoletti2, Luca Di Vito2, vito ramazzotti5,
alessandro manzoli5, Francesco Prati1
1San Giovanni Addolorata Hospital, CLI Foundation, Rome, Italy, 2CLI Foundation,
Rome, Italy, 3CSK MSWiA, Warsaw, Poland, 4Sandro Pertini Hospital, Rome, Italy,
5San Giovanni Addolorata Hospital, Rome, Italy
Background: Patients with ST-elevation myocardial infarction (STEMI) treated
with primary angioplasty tend to have worse procedural results due to the presence of
larger amount of residual intrastent thrombus. However little is known about the
relationship between residual intrastent thrombus and clinical outcome. Aim of the
present study was to explore the correlation between the amount of residual intrastent
thrombus burden and the clinical outcome in patients enrolled in the randomized
COCTAIL II trial
Methods: The study population consisted of 128 STEMI patients who underwent
primary PCI within 6 h from onset of chest pain and randomized to one of the
following four treatments: local infusion of abciximab delivered by the ClearWay with
(group 1) or without thrombectomy (group 2), intracoronary abciximab with (group 3)
or without thrombectomy (group 4). Residual intrastent thrombus burden at OCT
assessment was deﬁned as: number of cross section with residual thrombus
area >10% and mean Thrombus area % (average of % thrombus area in all stented
cross sections). All patients had a clinical assessment at a mean follow-up of 12  4
months./Suppl B j September 13–17, 2014 j TCT Abstracts/Thrombectomy
